Cardiac AI: Why Detection Wins 90% of Investment
If you follow the money in cardiac AI, it flows in two completely different directions. The capital reveals…
Healthcare AI Prediction: 30% Fewer Errors by 2026
Healthcare AI cuts diagnostic errors by 30%, reduces wait times, and identifies at-risk patients sooner. See how to…
Cardiac Prevention Science: 2026 Shift to Proactive Care
Understand the 2026 shift to proactive cardiac care. Learn about genetic screening, new lipid-lowering therapies, and integrated care.
The Paper Still Defining AI ECG Diagnosis
You see a lot of noise about AI in cardiology, new clearances, big funding rounds, promises of changing…
Eko’s EFAST: The Future of Cardiovascular AI Investment
The whole field of cardiovascular AI is shifting. We’re finally moving past narrow algorithms built for one specific…
AI Unlocks Undiagnosed Hypertension: A Billion Dollar Opportunity
Undiagnosed hypertension is a massive blind spot in global health. We’re missing millions of cases because traditional screenings,…
Cardiac AI Funding: Top 10 Companies & What It Means for Investors
The landscape of cardiovascular artificial intelligence (AI) is rapidly evolving, marked by a significant influx of capital that…
JAHA Publication: The Gold Standard for Cardiac AI Investment
The proliferation of artificial intelligence in healthcare has ushered in an era of unprecedented innovation, particularly within cardiology.…
HeartFlow’s Billion Dollar IPO: Clinical Evidence Driving Cardiac AI Valuation
The recent trajectory of HeartFlow, particularly its substantial capital raise and a deep evidentiary base, compels a rigorous…
HeartFlow’s 625+ Papers: The Billion Dollar Evidence Moat
The valuation of AI in healthcare often orbits a singular, undeniable truth: clinical evidence is the ultimate de-risking…